Talk Radioisotopes: Going Nuclear on Cancer
Talk Radioisotopes: Going Nuclear on Cancer
Podcast Description
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
Podcast Insights
Content Themes
The podcast centers on the evolving field of radiopharmaceuticals, covering essential topics such as targeted radiotherapies, regulatory challenges, and isotope supply chains. For example, episodes may delve into the implications of new isotopes for personalized cancer treatments or the impact of pharmaceutical companies entering the market.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
On this episode, hosts Scott and Sarah are joined by Matt Furlow, Associate Principal at ZS, about the evolving role of radiopharmaceuticals in oncology. With a PhD in bioengineering and a decade of consulting experience, Matt brings a unique perspective on how scientific insight and strategic planning intersect to help biotech and pharma companies bring new therapies to the market.
Matt shares how radiopharmaceuticals are following a path similar to antibody-drug conjugates and cell therapies. Which is attracting investment but facing challenges in logistics, site readiness, and workforce shortages. He explains why supply chain planning must start early, how regulatory requirements impact delivery sites, and why expanding access is critical for patient care. From radionuclide shortages to limited site accreditation, Matt outlines the practical hurdles companies must overcome.
The trio explores emerging isotopes like actinium and copper and the potential for radiopharmaceuticals to move into earlier lines of treatment. Emphasizing the need for a diverse therapeutic toolkit—tailored isotopes, targeting agents, and delivery mechanisms—to personalize cancer care. Matt closes with a bold vision: if key barriers can be addressed, radiopharmaceuticals could one day supplant traditional radiation therapy.
——–
Time Stamps:
- *(02:37) Matt’s Journey from Academia to Consulting
- *(05:29) The Current State of Radiopharmaceuticals
- *(08:34) Challenges found in the Radiopharmaceutical Supply Chain
- *(12:14) Exploring the Patient Journey and Logistics
- *(23:56) What is the Future of Radiopharmaceuticals?
——–
‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
——–
Links:
——-
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.